| Interacting proteins: P53602 and P38646 |
Pubmed |
SVM Score :0.0 |
| Mortalin MPD ( mevalonate pyrophosphate decarboxylase ) interactions and their role in control of cellular proliferation . ^^^ Mevalonate pyrophosphate decarboxylase ( MPD ) was identified as one of the mortalin binding partners . ^^^ |
|
| Interacting proteins: P53602 and P38646 |
Pubmed |
SVM Score :0.0 |
| To assess the role of glycogenolysis in mediating exercise induced increases in muscle water as monitored by changes in muscle proton relaxation times on magnetic resonance imaging ( MRI ) and cross sectional area ( CSA ) , five patients with myophosphorylase deficiency ( MPD ) were compared with seven controls . ^^^ The volume of exercised muscles , estimated by CSA , increased in both groups after handgrip ( controls : 13 . 8 + / 3 . 5 % , n = 7 , P less than 0 . 0001 ; MPD : 7 . 5 + / 1 . 5 % , n = 4 , P less than 0 . 005 ) , but the change was greater in controls ( P less than 0 . 02 ) . ^^^ |
|
| Interacting proteins: P53602 and P38646 |
Pubmed |
SVM Score :0.0 |
| Five other dogs were treated with TLI and received cyclosporine ( CsA ) and methylprednisolone ( MPd ) daily until graft rejection . ^^^ At the time of transplantation , the specific anti DLA antibody titers in the recipients were 81 to 243 in the untreated dogs ; 27 to 81 in the TLI ATG treated group , and 3 to 243 in the TLI CsA / MPd treated group . ^^^ The titers fell within 24 48 hr after renal transplantation , to 3 to 81 in the untreated sensitized dogs ; they were 3 to 9 in the TLI ATG treated group , and were 9 to 243 in the TLI CsA / MPd treated group . ^^^ The cytotoxic antibody titers reached postoperative peaks of 6500 to 200 , 000 in the untreated dogs ; 729 to 6500 in the TLI ATG treated dogs , and 243 to 6500 in the TLI CsA / MPd treated recipients . ^^^ The combined use of TLI and CsA / MPd can significantly inhibit the capacity of immunized recipients to muster a secondary humoral response to the DLA antigen ( s ) used in the sensitization process ; such treatment also abrogates the ability of the recipients to reject renal allografts bearing the same DLA specificities in accelerated fashion . ^^^ |
|